Hot flashes without hormones: what the trials of non-hormonal treatments show
How long hot flashes last, which non-hormonal treatments professional guidance supports, and what trials show for two new drugs, older medications, behavioral therapy, and supplements.

Hot flashes and night sweats last longer than most women are told. In a study that followed women through menopause, the median duration of frequent hot flashes was 7.4 years, and they continued for a median of 4.5 years after the final period. Women whose hot flashes began before their periods stopped had them longest, a median of more than 11.8 years. African American women reported the longest duration of any group, a median of 10.1 years (Avis et al., 2015).
Hormone therapy is the most effective treatment (North American Menopause Society, 2022). In November 2025 the Food and Drug Administration announced that it would remove most of the boxed warning that hormone products had carried for two decades. The agency's announcement refers to starting treatment before age 60 or within ten years of menopause (U.S. Food and Drug Administration). Even so, some women cannot take hormones, for example after breast cancer, and others prefer not to.
This article is for women who want relief from hot flashes without hormone therapy.
What professional guidance recommends
In 2023 the North American Menopause Society reviewed the evidence for non-hormonal options and sorted them into two lists (North American Menopause Society, 2023).
Recommended:
- Cognitive behavioral therapy
- Clinical hypnosis
- Certain antidepressants, known as SSRIs and SNRIs
- Gabapentin
- Fezolinetant
- Oxybutynin
- Weight loss and a nerve block called a stellate ganglion block, with a lower level of evidence
Not recommended for hot flashes:
- Supplements and herbal remedies, soy foods and soy extracts
- Paced breathing, relaxation, mindfulness, and yoga
- Cooling techniques and avoiding triggers
- Exercise
- Acupuncture, cannabinoids, and clonidine
The second list covers treatments for which trials have not shown an effect on hot flashes. Exercise and yoga have other benefits. They have not been shown to reduce hot flashes.
Two new drugs
Hot flashes start in a group of nerve cells in the brain's temperature control center. Estrogen normally keeps these cells in check. When estrogen falls, they become overactive. Two new drugs block the receptors through which these cells signal.
Fezolinetant was approved in 2023. In one phase 3 trial, women taking the 45-milligram dose had about 2.1 fewer hot flashes a day than women on placebo after four weeks and about 2.6 fewer after 12 weeks (Lederman et al., 2023). A second trial found a similar result (Johnson et al., 2023). In the first 12 weeks, side effects were reported by a similar share of women on the drug and on placebo, and raised liver enzymes were rare (Lederman et al., 2023). In 2024 the FDA added a warning about rare cases of serious liver injury. Liver blood tests are required before starting the drug and during treatment (U.S. Food and Drug Administration).
Elinzanetant was approved in October 2025 and is taken at bedtime. In two phase 3 trials, women began with an average of 13 to 16 moderate or severe hot flashes a day. After 12 weeks, those taking the drug had about 3.2 fewer a day than those on placebo. Sleep and menopause-related quality of life also improved (Pinkerton et al., 2024). A year-long trial of 628 women also found fewer hot flashes with the drug than with placebo at 12 weeks (Panay et al., 2025). The most common side effects listed on the label are headache, fatigue, dizziness, and sleepiness (Lynkuet prescribing information).
Elinzanetant has also been tested in women with hot flashes caused by hormone-blocking treatment for breast cancer. In a trial of 474 women, hot flashes fell by 6.5 a day after four weeks with the drug, compared with 3.0 a day with placebo (Cardoso et al., 2025).
Older medications
- Paroxetine at a low dose of 7.5 milligrams. In two trials with 1,184 women, it reduced the frequency of hot flashes more than placebo at 4 and 12 weeks (Simon et al., 2013). Paroxetine can interfere with tamoxifen, so women taking tamoxifen are usually offered something else.
- Gabapentin. In a trial of 600 women with seven or more hot flashes a day, an extended-release form reduced frequency and severity more than placebo, and reduced sleep disruption. At 12 weeks, 58 percent of women taking it rated themselves much or very much improved, compared with 44 percent on placebo (Pinkerton et al., 2014). Dizziness and drowsiness are the usual side effects.
- Oxybutynin, a bladder medication. In a trial of 150 women, both doses tested reduced hot flashes significantly more than placebo. Dry mouth was the main side effect (Leon-Ferre et al., 2020).
Treatments without medication
Cognitive behavioral therapy changes how disruptive hot flashes are. In a trial that compared group therapy, a self-help version, and no treatment, both forms of therapy reduced how much of a problem women rated their hot flashes and night sweats to be, and the benefit was still present at 26 weeks. Night sweats also became less frequent, and mood and quality of life improved (Ayers et al., 2012).
Clinical hypnosis has been tested in a randomized trial in postmenopausal women. After 12 weeks, the number of hot flashes women reported had fallen by 74 percent in the hypnosis group and by 17 percent in the comparison group. Hot flashes recorded by a skin sensor fell by 57 percent and 10 percent (Elkins et al., 2013).
Black cohosh is the best-known herbal remedy. A Cochrane review of 16 trials with 2,027 women found no significant difference between black cohosh and placebo in the frequency of hot flashes (Leach and Moore, 2012).
How the options compare
No trial has compared these treatments directly with one another, so the figures above cannot be ranked with confidence. Each trial enrolled different women and counted hot flashes in a slightly different way.
Two points are consistent. Women in the placebo groups also improved, often by a quarter or more, so part of the benefit seen with any treatment reflects time and attention. And beyond that placebo effect, the drugs reduce hot flashes by a few a day in women who start with ten or more. That is a meaningful change for many women, and it is not a cure.
Practical points
- Decide what bothers you most. If it is sleep, a treatment taken at night may suit you. If it is how disruptive the flashes feel, cognitive behavioral therapy is a reasonable first step.
- Give a medication four weeks before judging it. Most of the benefit in trials appeared by then.
- If you are taking tamoxifen or another breast cancer drug, tell the prescriber, since it affects which options are suitable.
- Ask about liver blood tests if you are prescribed one of the newer drugs.
- Save your money on supplements marketed for hot flashes. Trials have not shown that they work.
When to see a doctor
See a doctor if hot flashes or night sweats disturb your sleep or your work. Night sweats with fever, weight loss, or swollen glands, and hot flashes that begin many years after menopause, should be assessed, because they can have other causes.
Sources
- Duration of menopausal vasomotor symptoms over the menopause transition (Avis et al., JAMA Internal Medicine, 2015) — analysis of the Study of Women's Health Across the Nation cohort
- The 2022 hormone therapy position statement of The North American Menopause Society (North American Menopause Society, Menopause, 2022) — position statement
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (U.S. Food and Drug Administration) — news release, November 10, 2025
- The 2023 nonhormone therapy position statement of The North American Menopause Society (North American Menopause Society, Menopause, 2023) — position statement based on an evidence review
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study (Lederman et al., The Lancet, 2023) — randomized placebo-controlled phase 3 trial
- Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT (Johnson et al., Journal of Clinical Endocrinology & Metabolism, 2023) — randomized placebo-controlled phase 3 trial
- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause (U.S. Food and Drug Administration) — drug safety communication
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials (Pinkerton et al., JAMA, 2024) — two randomized placebo-controlled phase 3 trials, n=396 and n=400
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial (Panay et al., JAMA Internal Medicine, 2025) — randomized placebo-controlled phase 3 trial, n=628, 52 weeks
- Lynkuet (elinzanetant) prescribing information (U.S. Food and Drug Administration) — approved product label, October 2025
- Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer (Cardoso et al., New England Journal of Medicine, 2025) — randomized placebo-controlled phase 3 trial, n=474
- Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials (Simon et al., Menopause, 2013) — two randomized placebo-controlled trials, n=1,184
- Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause (Pinkerton et al., Menopause, 2014) — randomized placebo-controlled trial, n=600
- Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603) (Leon-Ferre et al., JNCI Cancer Spectrum, 2020) — randomized placebo-controlled trial, n=150
- Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial (Ayers et al., Menopause, 2012) — randomized controlled trial
- Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial (Elkins et al., Menopause, 2013) — randomized controlled trial
- Black cohosh (Cimicifuga spp.) for menopausal symptoms (Leach and Moore, Cochrane Database of Systematic Reviews, 2012) — Cochrane review of 16 randomized trials, n=2,027
This article is for general information and is not medical advice. Talk to your doctor before changing a medication, treatment or exercise program.



